Treatment of lipopolysaccharide- or CD14-mediated conditions using soluble CD14

摘要

Methods are provided for the treatment of symptoms of sepsis and other conditions that are mediated by the action of CD14 myelomonocytic antigen ("CD14"). The embodiments herein include treatments for symptoms of sepsis that are triggered by lipopolysaccharide ("LPS"). A genetically engineered recombinant soluble CD14 ("rsCD14") and fragments thereof are also provided. Both rsCD14 and a fragment thereof have been isolated and purified. The rsCD14 or fragments thereof can be administered to mammals to prevent or treat symptoms that are associated with sepsis.